|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-9-12
|
|
pubmed:abstractText |
The aim of the study was to determine the response rate and response duration of cervical cancer previously treated by cisplatin (with or without radiation) to a combination of docetaxel and gemcitabine. Secondary endpoints were assessment of toxicity and quality of life (QoL) of patients receiving the treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
123
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
105-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21723596-Adult,
pubmed-meshheading:21723596-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21723596-Cisplatin,
pubmed-meshheading:21723596-Deoxycytidine,
pubmed-meshheading:21723596-Drug Resistance, Neoplasm,
pubmed-meshheading:21723596-Female,
pubmed-meshheading:21723596-Humans,
pubmed-meshheading:21723596-Middle Aged,
pubmed-meshheading:21723596-Neoadjuvant Therapy,
pubmed-meshheading:21723596-Neoplasm Recurrence, Local,
pubmed-meshheading:21723596-Quality of Life,
pubmed-meshheading:21723596-Taxoids,
pubmed-meshheading:21723596-Uterine Cervical Neoplasms
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
|
|
pubmed:affiliation |
University of Leicester, Department of Cancer Studies & Molecular Medicine, Leicester, UK. rps8@le.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
